Locations:
SearchRomosozumab builds more bone than any previous medication
Bone fracture is a continual concern for people with osteoporosis. Until recently, osteoporosis patients were treated with either antiresorptive or anabolic medications. Antiresorptive medications help slow bone loss — although they do not stimulate bone formation. Anabolic medications stimulate bone formation — although they can stimulate bone resorption as well.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A new dual-acting drug, romosozumab, combines the benefits of earlier drugs, both increasing bone formation and decreasing bone resorption. Approved by the FDA in 2019, romosozumab builds more bone than any previous osteoporosis drug.
In this video, learn more about why romosozumab is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic partners with Palantir to create logistical command center
A Q&A with organizational development researcher Gina Thoebes
Cleveland Clinic transformation leader led development of benchmarking tool with NAHQ
Raed Dweik, MD, on change management and the importance of communication
Small business owners expand their networks and gain new insights
Leadership pearls from Margaret McKenzie, MD, hospital vice president
Advice from four CNOs on how to embrace innovation and collaboration
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items